Table 6.
GRADE evidence quality classification.
| Certainty assessment | № of patients | Effect | Certainty | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| № of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | TAICHI | comparison | Relative (95% CI) | Absolute (95% CI) | ||
| FPG | ||||||||||||
| 13 | randomized trials | seriousa | not serious | not serious | not serious | none | 641 | 630 | – | SMD 0.53 lower (0.88 lower to 0.18 lower) |
⨁⨁⨁◯ Moderatea |
CRITICAL |
| HbA1c | ||||||||||||
| 10 | randomized trials | not seriousa | not serious | not serious | not serious | none | 479 | 463 | – | MD 0.73 lower (0.98 lower to 0.49 lower) |
⨁⨁⨁⨁ Higha |
CRITICAL |
| Fins | ||||||||||||
| 6 | randomized trials | seriousa | not serious | not serious | not serious | none | 234 | 234 | – | SMD 0.48 lower (0.82 lower to 0.14 lower) |
⨁⨁⨁◯ Moderatea |
CRITICAL |
| Blood pressure | ||||||||||||
| 8 | randomized trials | seriousa | not serious | not serious | not serious | none | 546 | 542 | – | MD 3.8 lower (7.3 lower to 0.29 lower) |
⨁⨁⨁◯ Moderatea |
IMPORTANT |
| Blood lipid | ||||||||||||
| 9 | randomized trials | seriousa | not serious | not serious | not serious | none | 1683 | 1658 | – | SMD 0.38 lower (0.61 lower to 0.15 lower) |
⨁⨁⨁◯ Moderatea |
IMPORTANT |
| Inflammatory factor | ||||||||||||
| 6 | randomized trials | seriousa | not serious | not serious | not serious | none | 372 | 364 | – | SMD 1.38 lower (1.87 lower to 0.88 lower) |
⨁⨁⨁◯ Moderatea |
IMPORTANT |
CI, confidence interval; MD, mean difference; SMD, standardized mean difference; aThere was high heterogeneity in this study.